Dementia With Lewy Bodies Clinical Trial
Official title:
An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies
This research study is to examine the effects of the study medication Armodafinil in
patients with dementia with Lewy bodies (DLB).
DLB is associated with memory and other thinking problems, excessive daytime sleepiness,
hallucinations, delusions, apathy, and reduced quality of life.
One type of medication that could potentially improve daytime sleepiness, memory and
thinking skills, hallucinations, delusions, apathy, and quality of life is known as a
wake-promoting medication. Armodafinil is a wake-promoting medication that has been
developed for treatment of patients with narcolepsy, sleep apnea, and other disorders which
cause excessive daytime sleepiness.
The drug used in this study is considered investigational, which means it has either not
been approved by the Food and Drug Administration (FDA) for routine clinical use or for the
use described in this study. However the FDA has allowed the use of this drug/device in this
research study.
In this study, patients with DLB will receive daily oral Armodafinil tablets, and their
response to treatment will be assessed over 12 weeks. This study does not involve any
placebo medication, so all patients will receive Armodafinil treatment.
In patients with DLB, the following aims/objectives will be addressed by comparing data on
key measures at baseline and at 4 and 12 weeks of therapy:
Primary Aims - to test the hypotheses that armodafinil therapy at 150-250 mg every morning:
- will result in improvement in excessive daytime sleepiness as measured by the Epworth
Sleepiness Scale (ESS) and Maintenance of Wakefulness Test (MWT) (Aim 1A)
- will result in improvement in the cognitive subscale of the Alzheimer's Disease
Assessment Scale (ADAS-Cog) (Aim 1B)
- will result in improvement in the Alzheimer's Disease Cooperative Study-Clinician's
Global Impression of Change (ADCS-CGIC) (Aim 1C)
- will be well-tolerated with no significant side-effects present (Aim 1D)
Secondary Aims - to test the hypotheses that armodafinil therapy at 150-250 mg every morning
will result in improvement in:
- cognition as measured by the Mini-Mental State Examination (MMSE) and other focused
neuropsychological tests (Aim 2A)
- neuropsychiatric morbidity, particularly apathy, depression, visual hallucinations, and
delusions, as measured by the Neuropsychiatric Inventory (NPI) (Aim 2B)
- functional status as measured by the Alzheimer's Disease Cooperative Study-Activities
of Daily Living (ADCS-ADL) (Aim 2C)
- patient and caregiver quality of life (QOL) as measured by the linear analog scale
(LASA) (Aim 2D)
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03996460 -
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
|
Phase 2 | |
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
Recruiting |
NCT03672448 -
The China Longitudinal Aging Study of Cognitive Impairment
|
||
Completed |
NCT01340001 -
Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies
|
N/A | |
Not yet recruiting |
NCT04760860 -
Terazosin for Dementia With Lewy Bodies
|
Phase 1/Phase 2 | |
Completed |
NCT02910102 -
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
|
Phase 2 | |
Terminated |
NCT02928445 -
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
|
Phase 2/Phase 3 | |
Terminated |
NCT02871427 -
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
|
Phase 2 | |
Completed |
NCT05188105 -
Alpha tACS in Dementia With Lewy Bodies
|
N/A | |
Active, not recruiting |
NCT04167813 -
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
|
Phase 2 | |
Enrolling by invitation |
NCT04954183 -
Development of an EEG Diagnostic for Alzheimer's Disease
|
||
Recruiting |
NCT05326750 -
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
|
N/A | |
Completed |
NCT03907748 -
Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia
|
N/A | |
Completed |
NCT04649164 -
Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia
|
N/A | |
Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
Completed |
NCT05885620 -
SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia
|
N/A | |
Not yet recruiting |
NCT04555629 -
Advanced Cognitive Stimulation Therapy Hong Kong (ACST-HK)
|
N/A |